Trial Profile
A retrospective study to evaluate the effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ganciclovir; Valganciclovir
- Indications Cytomegalovirus infections
- Focus Pharmacodynamics
- 30 Dec 2015 New trial record